Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds

2026-01-23 07:30:00 ET

Thesis

Legend Biotech ( LEGN ) is set to present six new poster analyses on Carvykti at the 2026 Tandem Meetings. It should take place from February 4th to the 7th in Salt Lake. I expect the company to touch upon its durable efficacy, safety, and real-world outcomes across the current CARTITUDE trials. The company also now has over 10,000 patients treated worldwide and strong data showing us that earlier use in the multiple myeloma treatment continuum could lead to improved outcomes. This is the growth path for Legend. Carvykti is selling well and providing the company with the majority of its revenue. So any label extension to get approval for use in an earlier stage of treatment will be of great benefit. I see this as being the next big catalyst for the stock, and with the recent update from the FDA, I see the pathway as de-risked with the new changes, as I'll explain....

Read the full article on Seeking Alpha

For further details see: